Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Brief Summary: The purpose of this study is to compare the overall survival of patients treated with VTX-2337 + pegylated liposomal doxorubicin (PLD) versus those treated with PLD alone in women with recurrent or persistent, epithelial ovarian, fallopian tube or primary peritoneal cancer.

VTX-2337, a small molecule agonist of Toll-like Receptor 8 (TLR8), activates multiple components of the innate immune system and is being developed as a novel therapeutic agent for use in oncology. Experimental data obtained in an animal model of ovarian cancer supports the combination of VTX-2337 with PLD. In this model, the combination of VTX-2337 and PLD resulted in a significant reduction in tumor growth compared to either agent alone and an increase in the number of T lymphocytes infiltrating the tumor. The combination of PLD and VTX-2337 has been tested in a small number of women with ovarian cancer in a Phase 1b study and appears to be generally well-tolerated.


Options:
A: Arm Label: Arm 1: Niraparib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Niraparib | Arm Label: Arm 2: Niraparib and Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Niraparib | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Arm 2: Niraparib and Bevacizumab | Intervention Type: DRUG; Name: Niraparib; Assigned to Arm(s): Arm 1: Niraparib, Arm 2: Niraparib and Bevacizumab
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: SPARC147609 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Reference147609 | Intervention Type: DRUG; Name: SPARC147609; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Reference147609; Assigned to Arm(s): 2
C: Arm Label: Arm A: Chemotherapy + Bevacizumab + Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Bevacizumab, Drug: Chemotherapy, Drug: Placebos | Arm Label: Arm B: Chemotherapy + Bevacizumab + Atezolizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Atezolizumab, Drug: Chemotherapy | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Arm A: Chemotherapy + Bevacizumab + Placebo, Arm B: Chemotherapy + Bevacizumab + Atezolizumab | Intervention Type: DRUG; Name: Atezolizumab; Assigned to Arm(s): Arm B: Chemotherapy + Bevacizumab + Atezolizumab | Intervention Type: DRUG; Name: Chemotherapy; Assigned to Arm(s): Arm A: Chemotherapy + Bevacizumab + Placebo, Arm B: Chemotherapy + Bevacizumab + Atezolizumab | Intervention Type: DRUG; Name: Placebos; Assigned to Arm(s): Arm A: Chemotherapy + Bevacizumab + Placebo
D: Arm Label: PLD 40 mg/m2 plus VTX-2337; Type: EXPERIMENTAL; Interventions: Drug: pegylated liposomal doxorubicin (PLD), Drug: VTX-2337 | Arm Label: PLD 40 mg/m2 plus placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: pegylated liposomal doxorubicin (PLD), Drug: Placebo | Intervention Type: DRUG; Name: pegylated liposomal doxorubicin (PLD); Assigned to Arm(s): PLD 40 mg/m2 plus VTX-2337, PLD 40 mg/m2 plus placebo | Intervention Type: DRUG; Name: VTX-2337; Assigned to Arm(s): PLD 40 mg/m2 plus VTX-2337 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): PLD 40 mg/m2 plus placebo

Answer: D